MARKET

PBH

PBH

Prestige Consumer
NYSE

Real-time Quotes | Nasdaq Last Sale

52.70
+0.30
+0.56%
Opening 13:39 06/16 EDT
OPEN
52.18
PREV CLOSE
52.40
HIGH
52.75
LOW
52.17
VOLUME
51.48K
TURNOVER
--
52 WEEK HIGH
52.75
52 WEEK LOW
32.20
MARKET CAP
2.63B
P/E (TTM)
16.17
1D
5D
1M
3M
1Y
5Y
CFRA updates its best buys to play the vaccine-driven recovery
A look at plays for the COVID-19 vaccine recovery represents a second stab at such a list for the analysts at CFRA, which first took a run last September at
Seekingalpha · 06/03 23:15
PointsBet hires Canadian gaming industry veteran Nic Sulsky as they look to expand into Canadian market
, /PRNewswire/ -- PointsBet, a premier global online gaming operator, announced today that it has appointed as Chief Commercial Officer for their Canadian operations, effective , in a move that confirms PointsBet's intent to launch its products and servi...
PR Newswire - PRF · 06/03 13:00
--DA Davidson Adjusts Prestige Consumer Healthcare's Price Target to $52 from $49, Keeps Neutral Rating
MT Newswires · 05/28 10:18
DA Davidson Maintains Neutral on Prestige Consumer, Raises Price Target to $52
DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:PBH) with a Neutral and raises the price target from $49 to $52.
Benzinga · 05/28 10:15
Prestige Consumer (PBH) Looks Poised on E-Commerce Strength
Zacks.com · 05/27 13:00
Prestige Consumer buys Akorn Operating for $230 million in cash
Prestige Consumer Healthcare (PBH) inks an agreement to acquire a portfolio of over-the-counter consumer brands from specialty pharmaceutical company Akorn Operating Company LLC ((Akorn)) for $230 million in cash.The consumer
Seekingalpha · 05/27 12:51
BRIEF-Akorn Announces Agreement To Sell Its Consumer Health Business To Prestige Consumer Healthcare
reuters.com · 05/27 12:37
Prestige Announces Agreement to Expand Eye Care Offering with Acquisition of TheraTears
Acquisition adds TheraTears brand to Company’s leading eye care portfolioAcquisition expected to add approximately $60 and $20 million of Revenue and EBITDA, respectively on an annual basisTransaction expected to close during fiscal 2Q TARRYTOWN, N.Y., May...
GlobeNewswire · 05/27 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PBH. Analyze the recent business situations of Prestige Consumer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PBH stock price target is 52.75 with a high estimate of 59.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 366
Institutional Holdings: 61.56M
% Owned: 123.33%
Shares Outstanding: 49.91M
TypeInstitutionsShares
Increased
75
5.63M
New
38
604.52K
Decreased
87
5.28M
Sold Out
32
732.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.14%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/President/Chief Executive Officer/Director
Ronald Lombardi
Chief Financial Officer
Christine Sacco
Executive Vice President/Director of Sales/Director of Marketing
Adel Mekhail
Senior Vice President/General Counsel/Secretary
William PPool
Independent Director
John E. Byom
Senior Vice President
Jeffrey Zerillo
Lead Director/Independent Director
Gary Costley
Director
Celeste Clark
Independent Director
John Byom
Independent Director
Christopher Coughlin
Independent Director
Sheila Hopkins
Independent Director
James Jenness
Independent Director
Natale Ricciardi
Independent Director
Dawn Zier
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.475
09/27/2018
  • All
  • Financials
  • Insiders
More
About PBH
Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through two segments: North American Over-the-Counter (OTC) Healthcare, and International Over-the-Counter Healthcare. Its portfolio of OTC healthcare products includes core brands, such as DenTek specialty oral care products, Monistat women's health products, Nix lice treatment, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, The Doctor's NightGuard dental protector, Little Remedies pediatric over-the-counter products, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatment, BC and Goody's pain relievers, Beano gas prevention, Debrox earwax remover, and Gaviscon antacid.

Webull offers kinds of Prestige Consumer Healthcare Inc stock information, including NYSE:PBH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBH stock methods without spending real money on the virtual paper trading platform.